fda announcement semaglutide approves Ozempic® (semaglutide) as the only GLP-1 RA to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease The FDA has approved a

For people who stop using GLP-1 weight-loss drugs such as Ozempic, gaining the weight back might be the least of their concerns

SinojiaRShaikhMKodguleRBhosaleSMadasSVaidyaAet al

Compounds showing 10-fold improvements in maze learning or complete reversal of cognitive deficits in mice consistently fail to demonstrate meaningful clinical benefit

Tapering Protocol: To mitigate this, Iyengar suggested considering a dose taper over at least 20 weeks

These medications work by mimicking a hormone that tells your brain you are full and slows down the rate at which your stomach empties its contents into the small intestine

Type 2 diabetes - Diagnosis and treatment [Internet]